{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:46:58Z","timestamp":1789537618205,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03679-4","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:47:05Z","timestamp":1737704825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching"],"prefix":"10.1186","volume":"23","author":[{"given":"Liu","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Qingdong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Shunhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Guangsheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guangji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"2","key":"3679_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","volume":"72","author":"V Mazzaferro","year":"2020","unstructured":"Mazzaferro V, Gorgen A, Roayaie S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):364\u201377.","journal-title":"J Hepatol"},{"key":"3679_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"3679_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"8","key":"3679_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658\u201367.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3679_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/07853890.2022.2048416","volume":"54","author":"M Deng","year":"2022","unstructured":"Deng M, Li S, Wang Q, et al. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Ann Med. 2022;54(1):803\u201311.","journal-title":"Ann Med"},{"issue":"4","key":"3679_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3322\/caac.21779","volume":"73","author":"SM Ruff","year":"2023","unstructured":"Ruff SM, Diaz DA, Pitter KL, et al. Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma. CA Cancer J Clin. 2023;73(4):346\u201352.","journal-title":"CA Cancer J Clin"},{"key":"3679_CR7","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.aohep.2022.100737","volume":"27","author":"A Elvevi","year":"2022","unstructured":"Elvevi A, Laffusa A, Scaravaglio M, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022;27:100737.","journal-title":"Ann Hepatol"},{"issue":"6","key":"3679_CR8","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.21873\/anticanres.14282","volume":"40","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, Ricci AD, Tober N, et al. Second-line treatment in advanced biliary tract cancer: today and tomorrow. Anticancer Res. 2020;40(6):3013\u201330.","journal-title":"Anticancer Res"},{"issue":"4","key":"3679_CR9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.7150\/jca.67523","volume":"13","author":"T Sun","year":"2022","unstructured":"Sun T, Zhang W, Chen L, et al. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients. J Cancer. 2022;13(4):1282\u20138.","journal-title":"J Cancer"},{"issue":"8","key":"3679_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1007\/s00270-022-03108-z","volume":"45","author":"D Liu","year":"2022","unstructured":"Liu D, Wang J, Ma Z, et al. Treatment of unresectable intrahepatic cholangiocarcinoma using transarterial chemoembolisation with irinotecan-eluting beads: analysis of efficacy and safety. Cardiovasc Intervent Radiol. 2022;45(8):1092\u2013101.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"3679_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/hbsn.2016.11.02","volume":"6","author":"LJ Savic","year":"2017","unstructured":"Savic LJ, Chapiro J, Geschwind JH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatobiliary Surg Nutr. 2017;6(1):7\u201321.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"3","key":"3679_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.32074\/1591-951X-252","volume":"113","author":"S Sarcognato","year":"2021","unstructured":"Sarcognato S, Sacchi D, Fassan M, et al. Cholangiocarcinoma. Pathologica. 2021;113(3):158\u201369.","journal-title":"Cholangiocarcinoma Pathologica"},{"issue":"1","key":"3679_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.21037\/hbsn-22-555","volume":"12","author":"WJ Choi","year":"2023","unstructured":"Choi WJ, Sapisochin G. Pushing the limits for the surgical treatment of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2023;12(1):99\u2013104.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"6","key":"3679_CR14","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00268-009-9970-0","volume":"33","author":"A Guglielmi","year":"2009","unstructured":"Guglielmi A, Ruzzenente A, Campagnaro T, et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg. 2009;33(6):1247\u201354.","journal-title":"World J Surg"},{"issue":"2","key":"3679_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198\u2013222.","journal-title":"CA Cancer J Clin"},{"key":"3679_CR16","doi-asserted-by":"publisher","first-page":"1239168","DOI":"10.3389\/fimmu.2023.1239168","volume":"11","author":"CX Liao","year":"2023","unstructured":"Liao CX, Deng CS, Liang X, et al. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review. Front Immunol. 2023;11(14):1239168.","journal-title":"Front Immunol"},{"issue":"1","key":"3679_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12916-024-03381-4","volume":"19","author":"M Zhu","year":"2024","unstructured":"Zhu M, Jin M, Zhao X, et al. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma. BMC Med. 2024;19(1):165.","journal-title":"BMC Med"},{"issue":"1","key":"3679_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-018-5021-2","volume":"18","author":"H Mou","year":"2018","unstructured":"Mou H, Yu L, Liao Q, et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. BMC Cancer. 2018;18(1):1105.","journal-title":"BMC Cancer"},{"issue":"4","key":"3679_CR19","first-page":"100255","volume":"3","author":"W Li","year":"2022","unstructured":"Li W, Wang Y, Yu Y, et al. Toripalimab in advanced biliary tract cancer. Innov (Camb). 2022;3(4):100255.","journal-title":"Innov (Camb)"},{"issue":"10391","key":"3679_CR20","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet"},{"issue":"7","key":"3679_CR21","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cncr.23787","volume":"113","author":"JH Kim","year":"2008","unstructured":"Kim JH, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer. 2008;113(7):1614\u201322.","journal-title":"Cancer"},{"key":"3679_CR22","doi-asserted-by":"publisher","first-page":"111541","DOI":"10.1016\/j.ejrad.2024.111541","volume":"176","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Jiang N, Yin X, et al. Comparison of efficacy and safety of conventional transarterial chemoembolization and drug-eluting bead transarterial chemoembolization in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study. Eur J Radiol. 2024;176:111541.","journal-title":"Eur J Radiol"},{"issue":"1","key":"3679_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00432-022-04485-1","volume":"149","author":"M He","year":"2023","unstructured":"He M, Jiang N, Yin X, Xu A, Mu K. Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. J Cancer Res Clin Oncol. 2023;149(1):531\u201340.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3679_CR24","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12885-023-11350-y","volume":"12","author":"H Li","year":"2023","unstructured":"Li H, Zhang X, Zhao W, et al. Efficacy of CalliSpheres\u00ae microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis. BMC Cancer. 2023;12(1):970.","journal-title":"BMC Cancer"},{"issue":"6","key":"3679_CR25","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.4103\/jcrt.jcrt_2143_22","volume":"19","author":"H Zhang","year":"2023","unstructured":"Zhang H, Wu C, Chen M, et al. Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: efficacy, safety, and prognostic factors. J Cancer Res Ther. 2023;19(6):1525\u201332.","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"3679_CR26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s11845-021-02629-9","volume":"191","author":"G Zhao","year":"2022","unstructured":"Zhao G, Liu S, Zhang Y, et al. Irinotecan eluting beads-transarterial chemoembolization using Callispheres\u00ae microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases. Ir J Med Sci. 2022;191(3):1139\u201345.","journal-title":"Ir J Med Sci"},{"issue":"12","key":"3679_CR27","doi-asserted-by":"publisher","first-page":"e19276","DOI":"10.1097\/MD.0000000000019276","volume":"99","author":"J Luo","year":"2020","unstructured":"Luo J, Zheng J, Shi C, et al., et al. Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: a preliminary result from CTILC study. Med (Baltim). 2020;99(12):e19276.","journal-title":"Med (Baltim)"},{"key":"3679_CR28","doi-asserted-by":"publisher","first-page":"1112500","DOI":"10.3389\/fbioe.2022.1112500","volume":"10","author":"J Wang","year":"2023","unstructured":"Wang J, Xue Y, Liu R, et al. DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study. Front Bioeng Biotechnol. 2023;10:1112500.","journal-title":"Front Bioeng Biotechnol"},{"issue":"15","key":"3679_CR29","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.7150\/jca.39410","volume":"18","author":"TY Zhou","year":"2020","unstructured":"Zhou TY, Zhou GH, Zhang YL, et al. Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma. J Cancer. 2020;18(15):4534\u201341.","journal-title":"J Cancer"},{"issue":"2","key":"3679_CR30","doi-asserted-by":"publisher","first-page":"101460","DOI":"10.1016\/j.clinre.2020.05.008","volume":"45","author":"C Chen","year":"2021","unstructured":"Chen C, Qiu H, Yao Y, et al. Comprehensive predictive factors for CalliSpheres\u00ae microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol. 2021;45(2):101460.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"3679_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jvir.2022.02.005","volume":"33","author":"LB Young","year":"2022","unstructured":"Young LB, Tabrizian P, Sung J, et al. Survival analysis using albumin-bilirubin (ALBI) grade for patients treated with drug-eluting embolic transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2022;33(5):510\u2013e5171.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"3679_CR32","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s11845-024-03611-x","volume":"193","author":"S Liu","year":"2024","unstructured":"Liu S, Liu C, Wang Q, et al. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: a safety and efficacy analysis. Ir J Med Sci. 2024;193(3):1215\u201322.","journal-title":"Ir J Med Sci"},{"issue":"1","key":"3679_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1080\/10717544.2021.1943057","volume":"28","author":"G Zhao","year":"2021","unstructured":"Zhao G, Liu S, Chen S, et al. Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients. Drug Deliv. 2021;28(1):1356\u201362.","journal-title":"Drug Deliv"},{"issue":"2","key":"3679_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ajg.2024.01.012","volume":"25","author":"L Bian","year":"2024","unstructured":"Bian L, Yang J, Song Z. Risk factors of liver abscess and biloma formation after drug-eluting bead transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma. Arab J Gastroenterol. 2024;25(2):176\u201381.","journal-title":"Arab J Gastroenterol"},{"key":"3679_CR35","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen YP, Du XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226.","journal-title":"BMJ"},{"key":"3679_CR36","doi-asserted-by":"publisher","first-page":"1141148","DOI":"10.3389\/fimmu.2023.1141148","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang X, Li Y, et al. Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: a retrospective cohort study. Front Immunol. 2023;14:1141148.","journal-title":"Front Immunol"},{"issue":"12","key":"3679_CR37","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3679_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2022.09.004","volume":"78","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Khalil DN, Fabris L, Abou-Alfa GK. Rational development of combination therapies for biliary tract cancers. J Hepatol. 2023;78(1):217\u201328.","journal-title":"J Hepatol"},{"key":"3679_CR39","doi-asserted-by":"publisher","first-page":"624789","DOI":"10.3389\/fimmu.2021.624789","volume":"12","author":"Z Ren","year":"2021","unstructured":"Ren Z, Yue Y, Zhang Y, et al. Changes in the peripheral blood Treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles. Front Immunol. 2021;12:624789.","journal-title":"Front Immunol"},{"key":"3679_CR40","doi-asserted-by":"publisher","first-page":"889312","DOI":"10.3389\/fonc.2022.889312","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y, Liu S, Zhao GS, et al. Early changes in peripheral blood cytokine levels after the treatment of metastatic hepatic carcinoma with CalliSpheres microspheres drug-eluting beads transcatheter arterial chemoembolization. Front Oncol. 2022;12:889312.","journal-title":"Front Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03679-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03679-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03679-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:47:08Z","timestamp":1737704828000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03679-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3679"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03679-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the principles outlined in the Declaration of Helsinki and met all relevant requirements in China. Approval for the study was obtained from The Ethics Committee of Linyi Cancer Hospital, The Ethics Committee of Affiliated Zhongshan Hospital of Dalian University, The Ethics Committee of Affiliated Central Hospital of Dalian University of Technology. Due to the retrospective cohort study design, a waiver of documentation of consent was used; the waiver for consent was granted by The Ethics Committee of Linyi Cancer Hospital, The Ethics Committee of Affiliated Zhongshan Hospital of Dalian University, The Ethics Committee of Affiliated Central Hospital of Dalian University of Technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}